These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 3226000)

  • 1. [The studies of natural killer cell activity in uro-genital cancer patients--investigation of natural killer cell activity from the standpoint of stage and antitumor therapy of genito-urinary tract carcinomas].
    Fukasawa K
    Nihon Hinyokika Gakkai Zasshi; 1988 Feb; 79(2):239-45. PubMed ID: 3226000
    [No Abstract]   [Full Text] [Related]  

  • 2. [Immune parameters of peripheral blood in chemoembolization with microencapsulated anticancer drugs].
    Sato K; Abe R; Moriyama M; Kato T; Tsuchida S
    Gan To Kagaku Ryoho; 1989 Jan; 16(1):73-7. PubMed ID: 2783546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic value and potential subtypes of immune activity scores in three major urological cancers.
    Shi B; Qi J
    J Cell Physiol; 2021 Apr; 236(4):2620-2630. PubMed ID: 32853461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Open clinical uro-oncology trials in Canada.
    Mackenzie M; Rodrigues G; Winquist E
    Can J Urol; 2007 Aug; 14(4):3662-7. PubMed ID: 17784993
    [No Abstract]   [Full Text] [Related]  

  • 5. [Zeta chain level of T and NK cells in patients with renal-cell carcinoma and bladder cancer and its clinical significance].
    Han Y; Li CL; Lu L; Zhou CX; Ma WB; Wang DM; Zhang SR
    Zhonghua Zhong Liu Za Zhi; 2004 Mar; 26(3):158-60. PubMed ID: 15196436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Studies of the immunological effects of interleukin-2 in patients with bladder cancer and renal cell carcinoma.
    Hermann GG
    APMIS Suppl; 1993; 35():1-26. PubMed ID: 8251200
    [No Abstract]   [Full Text] [Related]  

  • 7. Harnessing Natural Killer Cell Function for Genitourinary Cancers.
    Bhardwaj N; Farkas AM; Gul Z; Sfakianos JP
    Urol Clin North Am; 2020 Nov; 47(4):433-442. PubMed ID: 33008494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment of advanced cancer of the urinary tract with interleukin-2 (IL-2)].
    Hara M; Terashima Y; Kanamori S; Senga Y; Kondoh Y; Ohhara M; Tsuboi N; Nishimura T; Akimoto M
    Hinyokika Kiyo; 1988 Oct; 34(10):1693-6. PubMed ID: 3266712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent advances in the use of therapeutic cancer vaccines in genitourinary malignancies.
    Surolia I; Gulley J; Madan RA
    Expert Opin Biol Ther; 2014 Dec; 14(12):1769-81. PubMed ID: 25212872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Immunological study of anti-cancer effects of human alpha interferon for advanced renal cell carcinoma].
    Marumo K; Hayakawa M; Murai M; Tazaki H
    Nihon Hinyokika Gakkai Zasshi; 1985 Jul; 76(7):965-73. PubMed ID: 4079199
    [No Abstract]   [Full Text] [Related]  

  • 11. [Studies on human natural killer (NK) cell activity against cell lines derived from malignant urinary tract tumors. Part 3: Effects of OK432 on human NK cell activity and proliferation of tumor cells].
    Hayakawa M; Marumo K; Nagakura K; Hata M; Fujioka T; Nakamura H; Murai M
    Nihon Hinyokika Gakkai Zasshi; 1984 Jul; 75(7):1124-33. PubMed ID: 6542157
    [No Abstract]   [Full Text] [Related]  

  • 12. Novel immunotherapies in GU malignancies.
    Drakaki A; McDermott DF
    Curr Oncol Rep; 2013 Jun; 15(3):224-31. PubMed ID: 23519772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Update uro-oncology: scientific meetings 2011].
    Hegele A; Skrobek L; Schrader AJ
    Aktuelle Urol; 2012 Jan; 43(1):13-27. PubMed ID: 22344822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genitourinary malignancy.
    Hudes GR; Ozols RF; Giantonio B
    Cancer Chemother Biol Response Modif; 1994; 15():531-54. PubMed ID: 7779598
    [No Abstract]   [Full Text] [Related]  

  • 15. An Overview of Emerging Immunotargets of Genitourinary Tumors.
    Montironi R; Santoni M; Cheng L; Lopez-Beltran A; Massari F; Matrana MR; Moch H; Scarpelli M
    Curr Drug Targets; 2016; 17(7):750-6. PubMed ID: 26648079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radio frequency ablation combined with interleukin-2 induces an antitumor immune response to renal cell carcinoma in a murine model.
    Kroeze SG; Daenen LG; Nijkamp MW; Roodhart JM; de Gast GC; Bosch JL; Jans JJ
    J Urol; 2012 Aug; 188(2):607-14. PubMed ID: 22704448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An assessment of the current use of human interferons in therapy of urological cancers.
    Horoszewicz JS; Murphy GP
    J Urol; 1989 Nov; 142(5):1173-80. PubMed ID: 2478725
    [No Abstract]   [Full Text] [Related]  

  • 18. Bioactivity of human GM-CSF gene therapy in metastatic renal cell carcinoma and prostate cancer.
    Simons JW
    Hinyokika Kiyo; 1997 Nov; 43(11):821-2. PubMed ID: 9436029
    [No Abstract]   [Full Text] [Related]  

  • 19. Perspectives on Geriatric Oncology Research presented at the 2019 American Society of Clinical Oncology Genitourinary Cancers Symposium.
    Shen J; Prentice M; Pollock Y; Franca M; Kanesvaran R
    J Geriatr Oncol; 2019 Jul; 10(4):523-525. PubMed ID: 30982753
    [No Abstract]   [Full Text] [Related]  

  • 20. Role of immunotherapy in the treatment of bladder and renal cell carcinoma.
    Stone NN; Droller MJ
    Semin Surg Oncol; 1991; 7(4):239-43. PubMed ID: 1925256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.